Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid LeukemiaClaude Preudhomme, François Guilhot, Joëlle Guilhot et al.|New England Journal of Medicine|2010Cited by 385
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, H. Jean Khoury et al.|Cancer Cell|2014Cited by 366